在欧洲申请专利的新选择
Reinhilde Veugelers1, Dietmar Harhoff2
1Reinhilde Veugelers is a professor at KU Leuven, Leuven, Belgium; a senior fellow at Bruegel, Brussels, Belgium; and a senior fellow at the Peterson Institute for International Economics, Washington, DC, USA.
概括
参与欧盟国家的发明者现在可以选择新的统一专利 (UP) 系统或传统的欧洲专利. 这种选择旨在加强泛欧洲专利格局,等待UP系统的更广泛采用.
科学领域:
- 知识产权法
- 欧盟的政策
- 创新管理
背景情况:
- 一个新的统一专利 (UP) 系统已在欧洲联盟 (EU) 的某些成员国实施.
- 这种系统为发明者提供了现有的欧洲专利途径的替代方案.
- 该系统旨在在多个欧盟国家简化专利保护.
相关概念视频
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Patch Clamp
5.6K
Many fundamental cell functions such as muscle contraction and nerve transmission rely on the electrical signals produced by the movement of positively and negatively charged ions across the cell membrane. One competent method to record current flowing across the whole cell or single ion channel is the patch-clamp technique.
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
5.6K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Nomenclature
1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K


